Rational design of peptide vaccines for autoimmune disease: harnessing molecular recognition to fix a broken network

References

• Hauser SL, Goodkin DE. Multiple Sderosis and other demyelinating diseases. In: Hanisoni Principles of Internal Medicine. McGraw Hill, OH, USA (2001).
   Google Scholar
• Drachman DB. Myasthenia Gravis and other diseases of the neuromuscular junction. In: Hanison Principles of Internal Medicine. McGraw Hill, OH, USA (2001).
   Google Scholar
• Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG. Medical Progress: Multiple Sclerosis N Engl. J. Med. 343, 938–952 (2000).
   Google Scholar
• Vandenbark AA, Chou YK, Whitham R etal. Treatment of multiple sclerosis with T-cell receptor peptides: results of a double-blind pilot trial. A& Med 10, 1109–1115 (1996).
   Google Scholar
• Zang Y, Hong J, Rivera V, Killian J, Zhang J. Preferential recognition of hypervariable region sequence by anti-idiotypic T-cells induced by T-cell vaccination in patients with multiple sclerosis. J. Immunol 164, 4011–4017 (2000).
   Google Scholar
• Bell RB, Lindsey JVV, Sobel RA, Hodgkinson S, Steinman L. Diverse T-cell receptor V beta gene usage in the central nervous system in experimental allergic encephalomyelitis. J. Immuno1.150, 4085–4092 (1993).
   Google Scholar
• Tejeda-Simon MV, Ying C, Yang D etal. Aberrant T-cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int. Immunol 12, 1642–1650 (2000).
   Google Scholar
• McCluskey J, Farris AD, Keech CL et al. Determinant spreading: lessons from animal models and human disease. Immunol Rev. 164, 209–229 (1998).
   PubMedGoogle Scholar
• Vanderlugt CL, Miller SD. Epitope spreading in immune mediated diseases: Implications for immunotherapy. Nat. Rev Immunol 2,85–95 (2002).
   PubMed Web of Science ®Google Scholar
• Vandenbark AA, Hashim G, Offner H. Immunization with a synthetic T-cell receptor V-region peptide protects against experimental autoimmune encephalomyelitis. Nature 341,541–544, (1989).
   Google Scholar
• •Among the first demonstrations that immunization with antigen receptor peptides can protect against autoimrnune disease by inducing anti-Id responses.
   Google Scholar
• Blalock JE. Genetic origins of protein shape and interaction rules. Nat. Mea! 1,876–878 (1995).
   PubMedGoogle Scholar
• •Theoretical discussion of hydropathy driven protein ineractions.
   Google Scholar
• Kamtekar S, Schiffer JM, Xiong H, Babik JM, Hecht MET. Protein design by binary patterning of polar and nonpolar amino acids. Science 262,1680–1685 (1993).
   Google Scholar
• Riddle DS, Santiago JV, Bray-Hall ST, Doshi N, Grantcharova VP, Yi Q, Baker D. Functional rapidly folding proteins from simplified amino acid sequences. Nat. Struct. Biol. 4,805–809 (1997).
   Google Scholar
• Weigent DA, Clarke BL, Blalock JE. Peptide design using a genetically patterned binary code: Growth hormone releasing hormone as a model. Immunomethoch 5, 91–97 (1992).
   Google Scholar
• Clarke BL, Blalock JE. Steroidogenic activity of a peptide specified by the reversed sequence of corticotropin mRNA. Roc. Abtl Arad Sc]. USA 87, 9708–9711 (1990).
   PubMedGoogle Scholar
• Akanuma S, Kigawa T, Yokoyama S. Combinatorial mutagenesis to restrict amino acid usage in an enzyme to a reduced set. Proc. Natl Acad. Sc]. USA. 99, 13549–13553 (2002).
   Google Scholar
• Blalock JE, Smith EM. Hydropathic anticomplementarity of amino acids based on the genetic code. Biochem. Biophys. Res. Comm 121, 203–207 (1984).
   PubMed Web of Science ®Google Scholar
• Baranyi L, Campbell W Ohshima Fujimoto, K. Boros, S. Okada, M. H. The antisense homology box: A new motif within proteins that encodes biologically active peptides. Nat. Med. 1, 894–901. (1995).
   PubMed Web of Science ®Google Scholar
• •Reviews reports on the role of hydropathy in ligand—receptor interactions.
   Google Scholar
• McGuigan JE. Antibodies to complementary petpides as probes for receptors. ImmunoMethoth — Complementary Peptides: Applications in Immunology and as Antibody Mmetics 5, 158–166 (1994).
   Google Scholar
• Eberle AN, Huber M. Antisense peptides of ACTH and MSH: tools for receptor isolation? In: Antisense Nucleic Acid and Proteins, Fundamentals and Applications. Mol NMJ, Krol RV-D (Eds). Marcel Dekker Inc., New York, NY, USA (1991).
   Google Scholar
• Guillemette G, Boutlay G, Gagnon S, Bosse R, Escher E. The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action. Biochem.j 269, 309 (1989).
   Google Scholar
• De Gasparo MS, Whitebread S, Einsle K, Huesser C. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor? Biochem. j 261, 310–311 (1989).
   Google Scholar
• Jurzak M, Pavo I and Fharenholz E Lack of interaction of vasopressin with its antisense peptides: a functional and immunological study. J. Chem. Soc. 1, 1407–1415 (1993).
   Google Scholar
• Rasmussen UB, Hesch HD. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem. Biophys. Res. Comm 149, 930–938 (1987).
   PubMedGoogle Scholar
• Martins VR, Graner E, Garcia-Abreu J et al. Complementary hydropathy identifies a cellular prion protein receptor. Nat. Med. 3, 1376–1382 (1997).
   PubMed Web of Science ®Google Scholar
• Ruiz-Opazo N, Hirayama K, Akimoto K, Herrera VLM. Molecular characterization of a dual endothelin-l/angiotensin II receptor. Md. Med. 4, 96–108 (1998).
   Google Scholar
• Ruiz-Opazo N, Akimoto K, Herrera VLM. Identification of a novel dual angiotensin/ vasopressin receptor: Direct evidence for the molecular recognition code hypothesis. Nat. Med. 1, 1074–1081 (1995).
   Google Scholar
• Goicoechea S, Pallero MA, Eggleton P, Michalak M, Murphy-Ullrich JE. The anti-adhesive activity of thrombospondin is mediated by the N-terminal domain of cell surface calreticulin. j Biol. Chem. 277, 37219–37228 (2002).
   Google Scholar
• Crawford SE, Stellmach V, Murphy-Ullrich JE et al. Thrombospondin-1 is a major activator of TGF-bl in viva Ce1193, 1159–1170 (1998).
   Google Scholar
• Fassina G, Consonni R, Zetta Land Cassani G. Design of hydropathically complementary peptides for Big Endothelin affinity purification. Lit. j Peptide Protein Res. 39, 540–548 (1992).
   Google Scholar
• Gho YS, Chae C-B. Anti-angiogenin activity of the peptides complementary to the receptor-binding site of angiogenin. j Biol. Chem. 272, 24294–24299 (1997).
   Google Scholar
• Villain M, Jackson PL, Manion MK et al. Be novo design of peptides targeted to the EF hands of calmodulin. j Biol. Chem 274, 2676–2685 (2000).
   Google Scholar
• •Demonstrates the use of hydropathy patterning to design peptides that will interact with a selected site.
   Google Scholar
• Smith LR, Bost KL, Blalock JE. Generation of idiotypic and anti-idiotypic antibodies by immunization with peptides encoded by complementary RNAs: A possible molecular basis for the network theory. j Immunol 138, 7–9 (1987).
   PubMed Web of Science ®Google Scholar
• •First demonstration of the production of an anti-Id Ab to a complementary peptide rather than an Id Ab.
   Google Scholar
• Bost KL, Blalock JE. Production of anti- idiotypic antibodies by immunization with a pair of complementary peptides. j Mol Recogn. 1, 179–183 (1987).
   Google Scholar
• Jerne NK. Towards a network theory of the immune system. Anna/es Immunologie (Institute Pasteur) 125 C, 373–389 (1974).
   Google Scholar
• Déry 0, Frobert Y, Zerari F, Conrath M, Grassi J, Couraud J-Y A monoclonal antibody directed at a substance P binding site in mammalian tissues: production and biochemical characterization. Neuropeptides 26\(Supp1.1), 2 (1994).
   Google Scholar
• Sagot M-A, Wijkhuisen S, Creminon C et al. A monoclonal antibody directed against the neurokinin-1 receptor contains a peptide sequence with similar hydropathy and functional properties to substance P, the natural ligand for the receptor. Mol Immunol 37, 423–433 (2000).
   PubMedGoogle Scholar
• ••Shows that the antigen-binding sites of manyAb carry an internal imagethat has similar hydropathic pattern to the original antigen, displaying that hydropathy drives antigen—antibody interactions.
   Google Scholar
• Selo I, Creminon C, Grassi J, Couraud J-Y Anti-allergen antibodies can be neutralized by antibodies obtained against a peptide complementary to the allergen: towards a new peptide therapy for allergy. Immunol Lett. 80, 133–138 (2002).
   PubMed Web of Science ®Google Scholar
• Reitan SK, Hannestad K. Immunoglobulin heavy chain constant regions regulate immunity and tolerance to idiotypes of antibody variable regions. Proc. Natl Acad. Li. USA 99, 7588–7593 (2002).
   PubMedGoogle Scholar
• Routsias JG, Touloupi E, Dotsika E etal. Unmasking the antiLa/SSB response in sera from patients with Sjogren's Syndrome by specific blocking of anti-idiotypic antibodies to La/SSB antigenic determinants. Mol Med 8, 293–305 (2002).
   Google Scholar
• ••Shows that circulating immune complexesof Id/anti-Id antibodies are present in the serum of humans with autoirnmune diseases and describes the use of ARM peptides in a novel method for detection of autoreactive Ab that may be undetectable due to Id/anti-Id networks in these patients.
   Google Scholar
• Araga S, LeBoeuf RD, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor. Proc. Natl Acad. Sci USA 90, 8747–8751 (1993).
   Google Scholar
• ••First use of an ARM peptide to protectagainst an autoimrnune disease — shows binding of pathogenic Ab and clinical protection against EAMG.
   Google Scholar
• Araga S, Galin FS, Kishimoto M, Adachi A, Blalock JE. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors. J. Immunol 157, 386–392 (1996).
   Google Scholar
• Araga S, Xu LK, Nakashima K, Villain M, Blalock JE. A peptide vaccine that prevents experimental autoimmune myasthenia gravis by specifically blocking T-cell help. FASEBJ 14, 185–196 (2000).
   Google Scholar
• •Uses an ARM peptide to vaccinate against T-cell help in EAMG.
   Google Scholar
• Yeh TM, Krolick KA. T-cells reactive with a small synthetic peptide acetylcholine receptor can provide help for a clonotypically heterogeneous antibody response and subsequently inpaired muscle function. J. Immunol 144,1654–1660 (1990).
   PubMed Web of Science ®Google Scholar
• Xu L, Villain M, Galin FS, Araga S, Blalock JE. Prevention and reversal of experimental autoimmune myasthenia gravis by a monoclonal antibody against acetylcholine receptor-specific T-cells. Cell Immunol 208, 107–114 (2000).
   Google Scholar
• Zhou S-R, Whitaker JN. Specific modulation of T-cells and murine experimental allergic encephalomyelitis by monoclonal anti-idiotypic antibodies. J. Immunol 150, 1629–1642 (1993).
   Google Scholar
• Zhou S-R, Whitaker JN. Active immunization with complementary peptide PBM 9–1: Preliminary evidence that it modulates experimental allergic encephalomyelitis in PUJ mice and Lewis rats. J. Neurosci. Res. 45, 439–446 (1996).
   Google Scholar
• ••Shows that immunization with an ARMin EAE is effective against against a T-cell disease, that it protects two different species and that anti-Id Ab anergizes autoreactive T-cell clones.
   Google Scholar
• Brostoff S, Burnett P, Lampert P, Eylar E. Isolation and characterization of a protein from sciatic nerve myelin responsible for experimental autoimmune neuritis. Nat. New Biol. 235, 210 (1972).
   PubMedGoogle Scholar
• Araga S, Kishimoto M, Doi S, Nakashima K. A complementary peptide vaccine that induces T-cell anergy and prevents experimental autoimmune neuritis in Lewis rats. J. Immunol 163, 476–482 (1999).
   PubMed Web of Science ®Google Scholar
• •Uses an ARIVI vaccine to protect against EAN.
   Google Scholar
• Genain CP, Abel K, Belmar N et al. Late Complications of Immune Deviation Therapy in a Nonhuman Primate. Science 274, 2054–2057 (1996).
   PubMed Web of Science ®Google Scholar
• Moutsopoulos NM, Routsias JG, Vlachoyiannopoulos PG, Tzioufas AG, Moutsopoulos HM. B-Cell epitopes of intracellular autoantigens: Myth and reality. Md. Med. 6, 141–151 (2000).
   Google Scholar
• Halse AK, Marthinussen MC, Wahren- Herlenius M, Jonsson R. Isotype distribution of antiRo/SS-A and antiLa/SS-B antibodies in plasma and saliva of patients with Sjogren's syndrome. Land. Rheumatol 29, 13–19 (2000).
   Google Scholar
• Zhang JZ, Rivera VM, Tejada-Simon MV etal. T-cell vaccination in multiple sclerosis: results of a preliminary study. J. Nemo]. 249, 212–218 (2002).
   Google Scholar
• Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte cells reactive against myelin basic protein. Nature 292, 60–61 (1981).
   Google Scholar
• Zhang J, Medaer R, Stinissen P, Hafler DA, Raus J. MHC restricted clonotypic depletion of human myelin basic protein reactive T-cells by T-cell vaccination. Science 261, 1451–1454 (1993).
   Google Scholar
• Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis Expert Rev Vaccines1 (3), 285–292 (2002).
   Google Scholar
• Oksenberg JR, Panzara MA, Begovich AB etal. Selection for T-cell receptor V beta-D beta-J beta gene rearrangements with specificity for a myelin basic protein peptide in brain lesions of multiple sclerosis. Nature 362, 68–70 (1993).
   Google Scholar
• Hong J, Zang YCQ, Tejada-Simon MV et al. A Common TCR V-D-J Sequence in V1313.1 T Cells Recognizing an Immunodominant Peptide of Myelin Basic Protein in Multiple Sclerosis. J. Immunol 163, 3530–3538 (1999).
   Google Scholar
• Noreager BD. Cross-reactive idiotypes: vaccine targets for autoimmune diseases. University of Alabama, Birmingham, AL, USA, PhD dissertation (2002).
   Google Scholar
• Sakaguchi S, Sakaguchi N, Shimizu J et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T-cells: their common role in controling autoimmunity, tumor immunity and transplantation tolerance. Immunol Rev 182, 18–32 (2002).
   Google Scholar
• Tzioufas AG Moutsopoulos HM. Epitopes and complementary epitopes of autoantigens: Candidate probes to study and modulate the autoimmune response. Clin. Exp. Rheum. 20, 289–291 (2002).
   PubMedGoogle Scholar
• McAnally JL, Xu L, Villain M, Blalock JE. The role of adjuvants in the efficacy of a peptide vaccine for myasthenia gravis. Soc. Exp. Biol. Med. 226, 307–311 (2001).
   PubMed Web of Science ®Google Scholar
• Madsen LS, Andersson EC, Jansson L etal. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat. Genet. 23, 343–347 (1999).
   Google Scholar
• Zhou EM, Kisil FT. Regulation of levels of serum antibodies to ryegrass pollen allergen Lol pIV by an internal image anti-idiotypic monoclonal antibody. Immunology 84, 343–349 (1995).
   PubMedGoogle Scholar
• Barker DS, Blalock JE. HyPSCAn. Unpublished computer application.
   Google Scholar